Carl Zeiss Meditec Posts Slight Revenue Growth
Currency effects and regional variations in business burden results
The Carl Zeiss Meditec Group achieved a balanced distribution of revenue across its three regions of the world in financial year 2013/2014. The development of its business units continued to be varied, however. A negative valuation result from currency hedging transactions reduced earnings per share, which reached € 0.92. The distribution of a regular dividend of 40 cents shall be proposed to the Annual General Meeting; the dividend ratio would therefore be slightly higher than the previous year, at around 43%.
Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, gave his take on the figures: "In spite of adverse currency trends and to some extent difficult markets, we have achieved a satisfactory result. The rise in case-number-dependent revenue is a very positive development. Once again, we achieved a significant increase in this area, to 28 percent."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.